Batoprotafib
As of the edition of 20 October 2026, Batoprotafib is a small molecule: in active development; acts on PTPN11.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 10, 5 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Bones, joints and muscles; Heart and blood vessels; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTPN11 | Tyrosine-protein phosphatase non-receptor type 11 | Q06124 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 1 | 1 | 5 |
| Phase 2 | 3 | 0 | 2 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2017 to now |
| Amgen | Lead sponsor of trials | 2019 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2020 to now |